FOCUSMED

FocusMed is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to developing innovative small molecule therapeutics for autoimmune and inflammatory diseases. The company's lead asset, FM-101, is a highly selective Janus kinase 1 (JAK1) inhibitor designed to offer superior safety and efficacy for conditions such as rheumatoid arthritis and atopic dermatitis. FocusMed's R&D strategy focuses on optimizing molecular selectivity to minimize off-target effects common in systemic treatments. With a leadership team comprising industry veterans from global pharmaceutical organizations, the company is advancing a pipeline of targeted therapies through various stages of clinical development. FocusMed aims to become a leader in the immunology space within the Chinese and global markets.